To assess the effect of Finerinone on slowing renal function decline and improving cardiovascular outcomes, particularly heart failure risk, in patients with diabetic CKD.
Adults aged ≥18 years.
Diagnosed cases of type 2 diabetes mellitus.
Chronic kidney disease with eGFR 25-90 mL/min/1.73m² and/or UACR ≥30 mg/g.
On stable ACE inhibitor or ARB therapy for at least 4 weeks.
Symptomatic heart failure (NYHA class II-IV).
eGFR <25 mL/min/1.73m² or on maintenance dialysis.
Known non-diabetic kidney disease.
Recent major cardiovascular event (within 30 days).
College of Physicians and Surgeons Pakistan
Lead sponsor
Nishtar Medical University
Sponsor institution